NextCure, Inc.

NXTC Nasdaq SEC CIK 1661059
Follow NextCure Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$6.8M +20.6% vs same quarter last year
EPS, diluted −$1.29 +59.9% vs same quarter last year
Operating cash flow −$12.1M −92.6% vs same quarter last year
Operating income −$6.9M +22.6% vs same quarter last year
Net income by quarter
−$11.6M
−$11M
−$26.8M
−$8.6M
−$9.4M
−$9.8M
−$14.9M
−$6.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$80M−$60M−$40M−$20M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$55.8M
FY24−$55.7M
FY23−$62.7M
FY22−$74.7M
FY21−$69.4M
FY20−$36.6M
FY19−$33.7M
FY18−$22.8M
FY17-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0$20MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$41.3M
FY23−$53.8M
FY22−$56M
FY21−$59.6M
FY20−$52.1M
FY19−$39M
FY18$4.9M
FY17-